PeptoPlus

← All products

RETA
Investigational, not approved

Retatrutide Injection 40 mg

Investigational triple agonist (GLP-1, GIP and glucagon) studied for obesity. Not an approved medicine.

Class
Triple agonist: GLP-1, GIP and glucagon
Used for
Weight loss (studied in trials)

Read the details Verify your code

PeptoPlus Retatrutide Injection 40 mg packaging

Mode of action

  • GLP-1 receptors: less appetite
  • GIP receptors: appetite and blood sugar control
  • Glucagon receptors: may raise energy use (being studied)

Purpose

Being studied for obesity and long-term weight management, and for related metabolic benefits.

Doses studied in the Phase 3 trial

4 mg9 mg12 mg

Not an approved dose. A vial's total peptide amount is not the same as its concentration per mL.

Route and status

Once a week under the skin, in trials only. Not an approved medicine or dosing advice. It cannot replace an approved drug; use only in authorized research.

Which receptors it switches on

ReceptorWhat it does
GLP-1Lowers appetite, slows stomach emptying, helps insulin releaseYes
GIPHelps insulin release and appetite and energy controlYes
GlucagonBeing studied for raising energy useYes

TRIUMPH-1: weight loss by dose

4 mg
19.0%
9 mg
25.9%
12 mg
28.3%
Placebo
2.2%
62.5%lost 25% or more on 12 mg
45.3%lost 30% or more on 12 mg (placebo: 0.5%)
65.3%dropped below BMI 30 on 12 mg

Source: Lilly TRIUMPH-1 release, May 21, 2026: 2,339 adults without diabetes. Investigational drug. Average % of body weight lost at 80 weeks.

Source: Jastreboff et al., NEJM (retatrutide for obesity); Lilly TRIUMPH-1 release, May 21, 2026. The label on every PeptoPlus unit hides a one-time code under a scratch layer, with a QR beside it. Scan it to check that the code was issued by PeptoPlus.